Analysis of Liquidity Ratios
Liquidity ratios measure the company’s ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Eli Lilly & Co., liquidity ratios
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Current ratio | 1.40 | 1.16 | 1.73 | 1.32 | 1.37 | |
Quick ratio | 0.85 | 0.68 | 1.20 | 0.91 | 0.98 | |
Cash ratio | 0.29 | 0.21 | 0.68 | 0.55 | 0.55 |
Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21).
Liquidity ratio | Description | The company |
---|---|---|
Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Eli Lilly & Co.’s current ratio deteriorated from 2018 to 2019 but then slightly improved from 2019 to 2020. |
Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Eli Lilly & Co.’s quick ratio deteriorated from 2018 to 2019 but then slightly improved from 2019 to 2020. |
Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Eli Lilly & Co.’s cash ratio deteriorated from 2018 to 2019 but then slightly improved from 2019 to 2020. |
Current Ratio
Eli Lilly & Co., current ratio calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Current assets | 17,462,100 | 13,709,600 | 20,549,600 | 19,202,100 | 15,101,400 | |
Current liabilities | 12,481,600 | 11,775,200 | 11,888,100 | 14,535,900 | 10,986,600 | |
Liquidity Ratio | ||||||
Current ratio1 | 1.40 | 1.16 | 1.73 | 1.32 | 1.37 | |
Benchmarks | ||||||
Current Ratio, Competitors2 | ||||||
Abbott Laboratories | 1.72 | 1.44 | 1.62 | 2.26 | 4.02 | |
AbbVie Inc. | 0.84 | 3.18 | 0.98 | 1.28 | 1.65 | |
Amgen Inc. | 1.81 | 1.44 | 2.79 | 5.49 | 4.11 | |
Bristol-Myers Squibb Co. | 1.58 | 1.60 | 1.61 | 1.55 | 1.55 | |
Gilead Sciences Inc. | — | 3.10 | 3.38 | 2.74 | 2.22 | |
Illumina Inc. | 3.60 | 6.69 | 2.49 | 3.99 | 3.29 | |
Johnson & Johnson | 1.21 | 1.26 | 1.47 | 1.41 | 2.47 | |
Merck & Co. Inc. | — | 1.24 | 1.17 | 1.33 | 1.78 | |
Pfizer Inc. | — | 0.88 | 1.57 | 1.35 | 1.25 | |
Regeneron Pharmaceuticals Inc. | 3.63 | 3.67 | 4.47 | 3.82 | 2.56 | |
Vertex Pharmaceuticals Inc. | 4.33 | 3.61 | 3.43 | 3.28 | 2.31 | |
Zoetis Inc. | 3.05 | 2.63 | 3.60 | 3.85 | 3.03 | |
Current Ratio, Sector | ||||||
Pharmaceuticals & Biotechnology | — | 1.57 | 1.73 | 1.82 | 2.10 | |
Current Ratio, Industry | ||||||
Health Care | — | 1.49 | 1.52 | 1.61 | 1.75 |
Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21).
1 2020 Calculation
Current ratio = Current assets ÷ Current liabilities
= 17,462,100 ÷ 12,481,600 = 1.40
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Eli Lilly & Co.’s current ratio deteriorated from 2018 to 2019 but then slightly improved from 2019 to 2020. |
Quick Ratio
Eli Lilly & Co., quick ratio calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Cash and cash equivalents | 3,657,100 | 2,337,500 | 7,998,200 | 6,536,200 | 4,582,100 | |
Short-term investments | 24,200 | 101,000 | 88,200 | 1,497,900 | 1,456,500 | |
Accounts receivable, net of allowances | 5,875,300 | 4,547,300 | 5,246,500 | 4,546,300 | 4,029,400 | |
Other receivables | 1,053,700 | 994,200 | 958,400 | 715,900 | 736,900 | |
Total quick assets | 10,610,300 | 7,980,000 | 14,291,300 | 13,296,300 | 10,804,900 | |
Current liabilities | 12,481,600 | 11,775,200 | 11,888,100 | 14,535,900 | 10,986,600 | |
Liquidity Ratio | ||||||
Quick ratio1 | 0.85 | 0.68 | 1.20 | 0.91 | 0.98 | |
Benchmarks | ||||||
Quick Ratio, Competitors2 | ||||||
Abbott Laboratories | 1.14 | 0.88 | 1.03 | 1.67 | 3.31 | |
AbbVie Inc. | 0.60 | 2.91 | 0.78 | 0.89 | 1.14 | |
Amgen Inc. | 1.30 | 1.01 | 2.44 | 4.98 | 3.68 | |
Bristol-Myers Squibb Co. | 1.28 | 1.26 | 1.37 | 1.30 | 1.27 | |
Gilead Sciences Inc. | — | 2.86 | 3.15 | 2.52 | 1.78 | |
Illumina Inc. | 3.18 | 6.00 | 2.23 | 3.43 | 2.75 | |
Johnson & Johnson | 0.91 | 0.94 | 1.08 | 1.04 | 2.04 | |
Merck & Co. Inc. | — | 0.78 | 0.72 | 0.83 | 1.24 | |
Pfizer Inc. | — | 0.50 | 0.84 | 0.93 | 0.84 | |
Regeneron Pharmaceuticals Inc. | 2.86 | 2.81 | 3.50 | 2.98 | 2.13 | |
Vertex Pharmaceuticals Inc. | 4.02 | 3.33 | 3.19 | 2.94 | 2.06 | |
Zoetis Inc. | 2.13 | 1.67 | 2.24 | 2.34 | 1.47 | |
Quick Ratio, Sector | ||||||
Pharmaceuticals & Biotechnology | — | 1.18 | 1.28 | 1.41 | 1.64 | |
Quick Ratio, Industry | ||||||
Health Care | — | 1.13 | 1.12 | 1.24 | 1.35 |
Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21).
1 2020 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 10,610,300 ÷ 12,481,600 = 0.85
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Eli Lilly & Co.’s quick ratio deteriorated from 2018 to 2019 but then slightly improved from 2019 to 2020. |
Cash Ratio
Eli Lilly & Co., cash ratio calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Cash and cash equivalents | 3,657,100 | 2,337,500 | 7,998,200 | 6,536,200 | 4,582,100 | |
Short-term investments | 24,200 | 101,000 | 88,200 | 1,497,900 | 1,456,500 | |
Total cash assets | 3,681,300 | 2,438,500 | 8,086,400 | 8,034,100 | 6,038,600 | |
Current liabilities | 12,481,600 | 11,775,200 | 11,888,100 | 14,535,900 | 10,986,600 | |
Liquidity Ratio | ||||||
Cash ratio1 | 0.29 | 0.21 | 0.68 | 0.55 | 0.55 | |
Benchmarks | ||||||
Cash Ratio, Competitors2 | ||||||
Abbott Laboratories | 0.60 | 0.38 | 0.45 | 1.08 | 2.82 | |
AbbVie Inc. | 0.30 | 2.56 | 0.47 | 0.59 | 0.66 | |
Amgen Inc. | 0.91 | 0.69 | 2.17 | 4.62 | 3.40 | |
Bristol-Myers Squibb Co. | 0.83 | 0.84 | 0.83 | 0.71 | 0.72 | |
Gilead Sciences Inc. | — | 2.50 | 2.84 | 2.19 | 1.29 | |
Illumina Inc. | 2.79 | 5.13 | 1.95 | 2.88 | 2.21 | |
Johnson & Johnson | 0.59 | 0.54 | 0.63 | 0.60 | 1.59 | |
Merck & Co. Inc. | — | 0.47 | 0.40 | 0.46 | 0.83 | |
Pfizer Inc. | — | 0.26 | 0.59 | 0.66 | 0.57 | |
Regeneron Pharmaceuticals Inc. | 1.33 | 1.53 | 1.95 | 1.24 | 0.84 | |
Vertex Pharmaceuticals Inc. | 3.55 | 2.85 | 2.83 | 2.59 | 1.81 | |
Zoetis Inc. | 1.66 | 1.07 | 1.39 | 1.43 | 0.65 | |
Cash Ratio, Sector | ||||||
Pharmaceuticals & Biotechnology | — | 0.81 | 0.90 | 1.01 | 1.23 | |
Cash Ratio, Industry | ||||||
Health Care | — | 0.73 | 0.72 | 0.85 | 0.94 |
Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21).
1 2020 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 3,681,300 ÷ 12,481,600 = 0.29
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Eli Lilly & Co.’s cash ratio deteriorated from 2018 to 2019 but then slightly improved from 2019 to 2020. |